Navigation Links
Chronic Hepatic Diseases Generate High Costs to Europe
Date:4/19/2012

e from principal experts in the field.

References

1. Fagiuoli S, et al, Societal burden in patients with Chronic Hepatic Diseases: the COME study results. Abstract presented at the International Liver Congress™ 2012.

2. Moreau R, et al, DIAGNOSIS, PREVALENCE, AND PROGNOSIS OF ACUTE-ON-CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE EASL-CHRONIC LIVER FAILURE (CLIF) CONSORTIUM CANONIC STUDY. Abstract presented at the International Liver Congress™ 2012.


    
    For further information on the studies, or to request an
    interview, please do not hesitate to contact the EASL Press
    Office on:
    Email: easlpressoffice@cohnwolfe.com
    Travis Taylor    Onsite tel: +44(0)7894-386-422
    Vicky O'Connor   Onsite tel: +44(0)7894-386-428


Video: http://multivu.prnewswire.com/mnr/prne/easl/53808/


'/>"/>
SOURCE European Association for the Study of the Liver
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
2. Study finds chronic abnormal brain blood flow in Gulf War veterans
3. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
4. Natures Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
5. "PATH B": A Comprehensive Support Programme in Europe for Patients Diagnosed With Chronic Hepatitis B Launched
6. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
7. GeNO LLC Receives Federal Grant To Advance Studies of Inhaled Nitric Oxide Product for the Treatment of Chronic Pulmonary Diseases
8. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
9. Cebixs Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes
10. Work by UH evolutionary biologist may one day help with chronic diseases
11. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... BURLINGAME, Calif. , April 16, 2015  Scientists ... session, "New Drugs on the Horizon," at the American ... Philadelphia, PA on Sunday, April 19, ... , Ph.D., Cleave,s Director of Biology, will present new ... CB-5083, a first-in-class, oral inhibitor of p97, a critical ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... MUMBAI, India, Aug. 25 ,Codexis, Inc., a ... a leading Indian active pharmaceutical ingredients (APIs) ... strategic,collaboration, expanding their three-year partnership in pharmaceuticals,manufacturing., ... will offer multiple pharmaceutical,intermediates and active pharmaceutical ...
... DETROIT, Aug. 25 For the first time in ... highly sophisticated,3D robotics through a single incision., "We ... us to,perform this type of procedure routinely," says Craig ... performed the delicate,operation last week using the da Vinci ...
... Vice President of Commercial Operations,and James Briggs Senior ... Aug. 25 Ikaria Holdings, Inc., a fully,integrated ... two key executives. Stephen A. Ross was appointed ... was named Senior Vice,President for Human Relations., ...
Cached Biology Technology:Codexis, Arch Announce Expanded Collaboration 2Codexis, Arch Announce Expanded Collaboration 3State's First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital 2Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... lab tests of "killer paper," a material intended for ... preserve foods by fighting the bacteria that cause spoilage. ... contains a coating of silver nanoparticles, which are powerful ... that silver already finds wide use as a bacteria ...
... Basque Institute for Agricultural Research and Development) have ... of infection by visna/maedi virus. This is a ... pneumonia, mastitis and neurological disorders. The study confirmed ... of the virus is the most likely path ...
... apple growers in the northeastern United States are faced ... tree nutrition and crop load. These and other problems ... (IFP) and organic fruit production (OFP) of apples, limiting ... recent issue of HortScience , Cornell University scientists ...
Cached Biology News:Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus 2Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus 3Integrated, organic production systems evaluated for 'liberty' apple 2
Normal serum collected from healthy Kunming mice....
Request Info...
... involves the optimization of immunostaining. ... of the primary antibody, selection ... (e.g. Alk. Phos., HRP, fluorescence, ... detection, evaluation by light or ...
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Biology Products: